This study aim to evaluate the efficacy and safety of zanubrutinib combined with R-CHOP in the treatment of DLBCL patients with p53 protein expression.
Age ≥18 years, ≤ 75 years, both sexes;
Diff use large B-cell lymphoma diagnosed by histopathology without previous systemic DLBCL treatment;
ECOG score: 0-2;
Predicted survival ≥3 months;
Patients with definite lymphoma central nervous system (CNS) infiltration, including brain parenchyma, meningeal invasion, or spinal cord compression;
severe or uncontrolled infection;
with active autoimmune disease;
Other serious medical conditions, such as uncontrolled diabetes, gastric ulcers, other serious cardiopulmonary diseases, etc. (the decision was left to the investigator);